替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响*

doi:10.3969/j.issn.1672-5069.2019.06.011

摘要/Abstract

摘要： 目的探讨应用替比夫定（LDT）联合阿德福韦酯（ADV）治疗慢性乙型肝炎（CHB）患者的效果及其对肾功能的影响。方法 2014年4月~2016年7月我院诊治的178例CHB患者,其中接受LDT治疗1年以上发生耐药者59例,接受ADV治疗1年以上发生耐药者59例和初始治疗的CHB患者60例,给予LDT联合ADV治疗,观察48 w。检测血清肌酐（Cr）水平,并计算估算的肾小球滤过率（eGFR）的变化。结果在治疗48 w末,初始治疗患者完全应答率为46.7%,显著高于LDT耐药组的28.8%或ADV耐药组27.1%,差异有统计学意义（P<0.05）;治疗前,三组血清Cr和eGFR水平无统计学差异（P>0.05）,在治疗48 w末,初始联合治疗患者血清Cr水平为（63.2±12.3） μmol/L,显著低于LDT耐药组患者的（71.2±14.3） μmol/L或ADV耐药组的（73.2±14.8） μmol/L（P<0.05）,而eGFR为（111.4±16.1） ml·min^-1·1.73m²,显著高于LDT耐药组的（99.7±13.4）ml·min^-1·1.73m² 或ADV耐药组的（99.3±13.1）ml·min^-1·1.73m²（P<0.05）。结论对于LDT或ADV治疗耐药的CHB患者采用LDT联合ADV继续治疗有效,或许能改善肾功能损伤,而初始联合治疗也值得进一步观察。

关键词: 慢性乙型肝炎, 替比夫定, 阿德福韦酯, 估算的肾小球滤过率, 治疗

Abstract: Objective To explore the impact of combination telbivudine（LDT） and adefovir dipivoxil （ADV） on renal functions in the treatment of patients with chronic hepatitis B. Methods 178 patients with CHB were recruited in our hospital between April 2014 and July 2016,and our patients with CHB included 59 patients with LDT resistant,59 with ADV resistant,and 60 naive. All patients received LDT and ADV combination therapy,and were followed-up for 48 weeks. The changes of serum creatinine（Cr） levels and estimated glomerular filtration rate（eGFR） were compared among the three groups. Results At the end of 48 weeks,the complete response rate in naive patients was 46.7%,significantly higher thant 28.8% in LDT resistant group or 27.1% in ADV resistant group（P<0.05）;before treatment,serum Cr levels and eGFR in the three groups were not significantly different （P>0.05）,while at the end of 48 weeks,serum Cr level in naive patients was （63.2±12.3）μmol/L,much lower than （71.2±14.3） μmol/L in LDT resistant or （73.2±14.8） μmol/L in ADV resistant group （P<0.05）,and the eGFR was （111.4±16.1） ml·min^-1·1.73m²,significantly higher than （99.7±13.4） ml·min^-1·1.73m² in LDT resistant or（99.3±13.1） ml·min-1·1.73m² in ADV resistant group（P<0.05）. Conclusion Application of LDT and ADV combination is effective in the treatment of patients with chronic hepatitis B with resistant hepatitis B viral mutation infection,and the de novo combination of the two nucleosides might be in clinical trial for decreasing HBV mutation.

Key words: Hepatitis B, Telbivudine, Adefovir dipivoxil, Estimated glomerular filtration rate, Therapy

石莹莹, 王元喜. 替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 820-823.

Shi Yingying, Wang Yuanxi.. Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B[J]. Journal of Practical Hepatology, 2019, 22(6): 820-823.

参考文献

[1] Wiens A,Lenzi L,Venson R,et al.Comparative efficacy of oral nucleoside or nucleotide analog monotherapy used in chronic hepatitis B:a mixed-treatment comparison Meta-analysis. Pharm-acotherapy,2013,33(12):144-151.
[2] Craxi A,Pawlotsky JM.European association for the study of the liver. EASL clinical practice guidelines:Management of hepatitis C virus infection. J Hepatol,2011,55(1):245-264.
[3] Hou JL,Wang GQ,Wang FS,et al.Guideline of prevention and treatment for chronic hepatitis B. J Clin Transl Hepatol,2017,5(4):297-318.
[4] Guclu E,Karabay O.Choice of drugs in the treatment of chronic hepatitis B in pregnancy. World J Gastroenterol,2013,19(14):1671-1672.
[5] Hadziyannis S,Tassopoulos N,Heathcote J,et al.Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med,2005,352(26):2673-2681.
[6] Wanang Y,Thongsawat S,Gane EJ,et al.Efficacy and safety of continuous 4-year telbivudine treatment in patients with chronic hepatitis B. J Viral Hepat,2013,20(4):37-46.
[7] Yang Q,Shi Yu,Yang Y,et al.Association between adefovir dipivoxil treatment and the risk of renal insufficiency in patients with chronic hepatitis B:a Meta-analysis. Biomed Rep,2015,3(2):269-275.
[8] 徐静,鲍磊,王玉,等. 替比夫定联合阿德福韦酯与拉米夫定联合阿德福韦酯治疗慢性乙型肝炎对肾功能影响的对比研究. 中华肝脏病杂志,2018,26(4):288-292.
[9] 中华医学会肝病学分会和感染病学分会.慢性乙型肝炎防治指南(2015年版).实用肝脏病杂志,2016,19(3):Ⅴ-.
[10] National Kidney Foundation.KDoQI clinical practice guidelines or chronic kidney disease:evaluation,classification,and ratification. Am J Kidney Dis,2002,39(2):11-66.
[11] Mori S,Fujiyama S.Hepatitis B?virus reactivation associated with antirheumatic therapy:Risk and prophylaxis recommendations. World J Gastroenterol, 2015,21(36):10274-10289.
[12] 罗丹,陈勇,陈清,等. 聚乙二醇干扰素α-2b治疗慢性乙型肝炎患者外周血T淋巴细胞亚群和血清细胞因子水平变化. 实用肝脏病杂志,2018,21(2):200-203.
[13] 邱英锋,王淑英. 长期应用恩替卡韦治疗拉米夫定耐药的慢性乙型肝炎患者临床疗效及安全性分析. 实用肝脏病杂志,2018,21(2):196-199.
[14] Stanaway JD,Shepard DS,Undurraga EA,et al.The global burden of dengue:an analysis from the global burden of disease study 2013. Lancet Infect Dis,2016,16(6):712-723.
[15] Jorgensen C,Chen S,Carnes CA,et al.“Know hepatitis B:”A multilingual communications campaign promoting testing for hepatitis B among Asian Americans and Pacific islanders. Public Health Rep,2016,131(Suppl 2):35-40.
[16] Kim YJ,Cho HC,Sinn DH,et al.Frequency and risk factors of renal impairment during long-term adefovir dipivoxil treatment in chronic hepatitis B patients. J Gastroen Hepatol,2012,27(2):306-312.
[17] Wu X,Cai S,Li Z,et al.Potential effects of telbivudine and entecavir on renal function:a systematic review and Meta-analysis. Virol J,2016,13(14):64-66.
[18] Liaw Y,Leung N,Kao J,et al.Asian-Pacific consensus statement on the management of chronic hepatitis B:a 2008 update. Hepatol Int,2008,2(3):263-283.
[19] Magalhaes-Costa P,Matos L,Barreiro P,et al.Fanconi syndrome and chronic renal failure in a chronic hepatitis B monoinfected patient treated with tenofovir. Rev Esp Enferm Dig,2015,107(23):512-514.
[20] Lee M,Oh S,Lee HJ,et al.Telbivudine protects renal function in patients with chronic hepatitis B infection in conjunction with adefovir-based combination therapy. J Viral Hepat,2014,21(12):873-881.

替比夫定联合阿德福韦酯治疗慢性乙型肝炎患者效果及其对肾功能的影响^*

Impact of combination telbivudine and adefovir dipivoxil on renal functions in the treatment of patients with chronic hepatitis B

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	鲍应军, 任伟新. 门静脉血栓介入治疗研究进展[J]. 实用肝脏病杂志, 2019, 22(6): 768-769.
[2]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[3]	. 肝纤维化诊断及治疗共识（2019年）[J]. 实用肝脏病杂志, 2019, 22(6): 793-803.
[4]	朱凌云, 张茂海, 崔莎莎, 张秋萍. 慢性乙型肝炎患者血清IL-12、IL-18水平和外周血单个核细胞FOXp3基因水平研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 816-819.
[5]	闵峰, 黄文琪, 吴卫兵, 张丽, 范荣华. 慢性乙型肝炎患者血清脂肪细胞因子水平变化及其临床意义^*[J]. 实用肝脏病杂志, 2019, 22(6): 824-827.
[6]	张迎明, 申爽, 田飞, 孙园园. IFNL4和IL-28B基因多态性检测评估慢性乙型肝炎患者抗病毒治疗应答价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 828-831.
[7]	邢欣, 魏重操, 周咪咪, 李小玲, 邓江, 鲁晓岚. 牛磺熊去氧胆酸与熊去氧胆酸治疗非酒精性脂肪性肝病患者疗效和安全性的Meta分析[J]. 实用肝脏病杂志, 2019, 22(6): 852-855.
[8]	段楚瑶, 陈庆山, 汪黎明, 贺晓琪. 熊去氧胆酸治疗妊娠期肝内胆汁淤积症患者疗效研究^*[J]. 实用肝脏病杂志, 2019, 22(6): 864-867.
[9]	陈梅梅, 段晓燕, 曹海霞, 丁雯瑾. 复方鳖甲软肝片治疗原发性胆汁性肝硬化患者疗效分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 880-883.
[10]	马雅琼, 李芝兰, 夏冰. 早期肠内营养联合微生态制剂治疗肝性脑病患者肠道菌群的改变^*[J]. 实用肝脏病杂志, 2019, 22(6): 892-895.
[11]	冯文广, 姜伟, 宋国军. PPV指导术中液体治疗对行肝部分切除术治疗的肝内胆管结石患者术后并发症发生的影响^*[J]. 实用肝脏病杂志, 2019, 22(6): 912-915.
[12]	黎秋曦, 贾健锋, 黄锐. 区段肝蒂肝切除术与B超引导下肝切除术治疗肝胆管结石患者临床价值分析^*[J]. 实用肝脏病杂志, 2019, 22(6): 916-919.
[13]	李传杰, 徐静, 王亮亮, 潘劲劲, 刘波. 恩替卡韦治疗慢性乙型肝炎患者血清HBsAg变化与病毒学应答的相关性研究[J]. 实用肝脏病杂志, 2019, 22(6): 928-929.
[14]	张瑞, 王剑, 陈世耀. 肝硬化门脉高压症并发血栓形成机制和治疗研究进展^*[J]. 实用肝脏病杂志, 2019, 22(6): 930-933.
[15]	梁巨波, 苗琪, 马雄. 胆管细胞型胆汁淤积诊治进展[J]. 实用肝脏病杂志, 2019, 22(6): 941-943.